Suhas has been with the Office of Generic Drugs since 2003. Since joining OGD she has
been involved with several committees and working groups in CDER’s Office of Pharmaceutical Science (OPS) and OGD including Good Review Practices working group, Stability working group, Inactive ingredients working group, Process Analytical Technology (PAT) committee, and Quality by Design (QbD) for modified release products working group. She has provided guidance to International Regulatory Authorities as part of the faculty for CDER Forum. Prior to joining OGD she was a faculty member at Penn State University and has spent several years in pharmaceutical industry at Novartis Inc. and in generics.